Universal Flu Vaccine Co BiondVax Pharmaceuticals Mulls NY IPO
Universal flu vaccine developer BiondVax Pharmaceuticals Ltd. (TASE:BNDX) is mulling a Wall Street IPO, sources inform “Globes.” The company has a market cap of NIS 42 million on the Tel Aviv Stock Exchange (TASE).
BiondVax is exploring two options either a conventional offering or listing American Depositary Receipts (ADR) for trading. The company will be required to file a prospectus with the US Securities and Exchange Commission (SEC) and the bookrunner is likely to be Aegis.
Help employers find you! Check out all the jobs and post your resume.
BiondVax is exploring two options either a conventional offering or listing American Depositary Receipts (ADR) for trading. The company will be required to file a prospectus with the US Securities and Exchange Commission (SEC) and the bookrunner is likely to be Aegis.
Help employers find you! Check out all the jobs and post your resume.